RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
ARYx Therapeutics - Stock

ARYx Therapeutics P/E 2024

ARYx Therapeutics P/E

-0.01

Ticker

ARYX

ISIN

US0433871094

As of Jun 19, 2024, ARYx Therapeutics's P/E ratio was -0.01, a -96.15% change from the -0.26 P/E ratio recorded in the previous year.

The ARYx Therapeutics P/E history

ARYx Therapeutics Aktienanalyse

What does ARYx Therapeutics do?

ARYx Therapeutics Inc is a pharmaceutical company founded in 1997 and based in Fremont, California. The company focuses on developing innovative patented therapies for the treatment of heart diseases and other metabolic diseases. The company's business model is based on recognizing the need for new and more effective medications and focusing on the discovery and development of such therapies. ARYx Therapeutics relies on a network of experienced professionals and a rigorous research and development program. ARYx Therapeutics has several divisions, including the development of therapies for the treatment of cardiac arrhythmias, as well as metabolic diseases such as diabetes and hypercholesterolemia. In addition, the company has developed a range of products that interact with the body in innovative ways by activating or blocking specific receptors. ARYx Therapeutics' most well-known product is the antiarrhythmic drug Dronedaron. It is the first antiarrhythmic drug to receive the safety standards of the US Food and Drug Administration (FDA) and offers an effective, safe, and well-tolerated treatment for atrial fibrillation. Dronedaron is currently approved in Europe and the US and is used worldwide by doctors and hospitals as an important treatment option. Another successful product from ARYx Therapeutics is the therapeutic agent NTP-2007. It was developed to increase insulin sensitivity and improve blood sugar control in patients with type 2 diabetes. NTP-2007 utilizes a novel mechanism that enhances the effect of insulin in the body without lowering blood sugar levels. It is currently being tested in clinical trials and showing promising results. Another promising product from ARYx Therapeutics is the anesthetic Fexinidazole. It is an innovative anesthetic that works in a unique way in the body and ensures fast and effective anesthesia without causing negative side effects. Fexinidazole is currently being tested in clinical trials and could prove to be an important innovation in anesthesiology. Overall, ARYx Therapeutics has established itself as a leading company in the research and development of innovative therapies for the treatment of heart diseases and metabolic diseases. The company aims to meet the needs of patients and medical professionals and improve global healthcare by pushing the boundaries of science and technology in medicine. ARYx Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/E Details

Deciphering ARYx Therapeutics's P/E Ratio

The Price to Earnings (P/E) Ratio of ARYx Therapeutics is a vital metric that investors and analysts use to determine the company’s market value relative to its earnings. It is calculated by dividing the current stock price by the earnings per share (EPS). A higher P/E ratio could suggest that investors are expecting higher future growth, while a lower ratio may indicate a potentially undervalued company or lower growth expectations.

Year-to-Year Comparison

Assessing ARYx Therapeutics's P/E ratio on a yearly basis provides insights into the valuation trends and investor sentiment. An increasing P/E ratio over the years signifies growing investor confidence and expectations for future earnings growth, while a decreasing ratio may reflect concerns over the company's profitability or growth prospects.

Impact on Investments

The P/E ratio of ARYx Therapeutics is a key consideration for investors aiming to balance risk and reward. A comprehensive analysis of this ratio, in conjunction with other financial indicators, aids investors in making informed decisions regarding buying, holding, or selling the company’s stocks.

Interpreting P/E Ratio Fluctuations

Fluctuations in ARYx Therapeutics’s P/E ratio can be attributed to various factors including changes in earnings, stock price movements, and shifts in investor expectations. Understanding the underlying reasons for these fluctuations is essential for predicting future stock performance and assessing the company's intrinsic value.

Frequently Asked Questions about ARYx Therapeutics Stock

What is the price-to-earnings ratio of ARYx Therapeutics?

The price-earnings ratio of ARYx Therapeutics is currently -0.01.

How has the price-earnings ratio of ARYx Therapeutics changed compared to last year?

The price-to-earnings ratio of ARYx Therapeutics has increased by -96.15% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of ARYx Therapeutics high compared to other companies?

Yes, the price-to-earnings ratio of ARYx Therapeutics is high compared to other companies.

How does an increase in the price-earnings ratio of ARYx Therapeutics affect the company?

An increase in the price-earnings ratio of ARYx Therapeutics would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of ARYx Therapeutics affect the company?

A decrease in the price-earnings ratio of ARYx Therapeutics would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of ARYx Therapeutics?

Some factors that influence the price-earnings ratio of ARYx Therapeutics are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does ARYx Therapeutics pay?

Over the past 12 months, ARYx Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, ARYx Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of ARYx Therapeutics?

The current dividend yield of ARYx Therapeutics is .

When does ARYx Therapeutics pay dividends?

ARYx Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of ARYx Therapeutics?

ARYx Therapeutics paid dividends every year for the past 0 years.

What is the dividend of ARYx Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is ARYx Therapeutics located?

ARYx Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von ARYx Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of ARYx Therapeutics from 6/19/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/19/2024.

When did ARYx Therapeutics pay the last dividend?

The last dividend was paid out on 6/19/2024.

What was the dividend of ARYx Therapeutics in the year 2023?

In the year 2023, ARYx Therapeutics distributed 0 USD as dividends.

In which currency does ARYx Therapeutics pay out the dividend?

The dividends of ARYx Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von ARYx Therapeutics

Our stock analysis for ARYx Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of ARYx Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.